Will Lagging Generic Approval Rates Increase FDA Backlog?

Eileen Oldfield, Associate Editor
Published Online: Friday, July 11, 2014
Follow Pharmacy_Times:
Generic drug approvals for the first 6 months of fiscal year 2014 are noticeably fewer than for the same period in 2013, despite an abundance of Accelerated New Drug Applications (ANDAs).

In the first 6 months of the 2014 fiscal year, the FDA has not approved nearly as many ANDAs as it did in 2013, despite receiving 597 submissions. According to its activities report, the FDA approved 196 ANDA applications between October 1, 2013, and March 31, 2014. Sixty-three of the ANDAs approved are for first-time generics.

During that same period in the 2013 fiscal year, the FDA approved 227 ANDAs, including 61 first-time generic drugs.

The FDA received 992 original ANDAs during the 2013 fiscal year, and issued 71 refuse-to-receive notifications, according to the FDA’s annual user-fee report. Of those applications, 428 received approval, and 106 of the drugs approved were first-time generics.

The FDA issued 1500 complete response letters, which detail problems with drug applications or additional information the FDA needs in order to make a determination on the drug, according to its annual Performance Report to the President and Congress for the Generic Drug User Fee Amendments.

According to its drug approval information page, common problems include unanticipated safety issues and manufacturing concerns, including failure to meet good manufacturing practice standards.

Meanwhile, the FDA has issued 694 complete response letters thus far during the 2014 fiscal year. The FDA has also issued 91 refuseto- receive notices, which it issues when it receives an incomplete application.

The growing backlog could prevent the FDA from meeting a major Generic Drug User Fee Act (GDUFA) goal involving ANDAs. GDUFA’s year goals include reviewing and acting on 90% of ANDAs, ANDA amendments, and ANDA prior-approval supplements.

In addition, generic manufacturers will soon face new stability requirements when submitting their applications after June 20, 2014, nearly a year after the final guidance appeared in the Federal Register.

Under the new stability guidelines, applicants would need to submit data from 3 pilot scale batches or 2 pilot scale batches and 1 small-scale batch. The batches would need to meet certain size requirements. According to a clarification on its guidance, chewable, disintegrating, immediate-release, extended-release, and delayed-release oral medication applications should be submitted with 2 batches at either 10% of the proposed production batch or 100,000 dosage units, whichever is greater. Although the third batch can be smaller than the 10% proposed production batch, it should not be smaller than 25% of the pilot scale batch. The FDA has additional specifications for powder, topical, and inhalation formulas tailored to those particular formulations.

Applicants must provide reasons if their batch does not meet the stability requirements. The applications must also contain 6 months of stability data including accelerated and long-term stability conditions, and data must use multiple product lots when it is appropriate.

Once the new guidance goes into effect, the manufacturing and packing process for the ANDA must reflect that of the commercial process. Applicants will also need to provide a fully packaged primary batch.

Manufacturers submitting amendments to ANDAs after June 20, 2014, will not be held to the new requirements, however. Instead, those applications will be evaluated according to the standards in place during their original submission date.

Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Mylan Inc. today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
A bill to make pharmacy benefit managers’ reimbursements for generic drugs more transparent will cover more federal health care programs than a bill introduced earlier this year.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times